New drugs for Clostridium difficile infection

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 428-431

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NEW DRUG; NITAZOXANIDE; OPT 80; POLYMER; PROBIOTIC AGENT; RAFALAZIL; RAMOPLANIN; TOLEVAMER; TOXOID; UNCLASSIFIED DRUG; VACCINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LETHALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENCE RISK; REINFECTION; RELAPSE; TREATMENT RESPONSE; TYPHLITIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; POLYSTYRENES;

EID: 33746643774     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506387     Document Type: Note

References (40)

1. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
2. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.
3. Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193:1143-50.
4. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
5. Bartlett JG. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89:1192-5.
6. Fekety R, Silva J, Armstrong J, et al. Treatment of antibiotic-associated enterocolitis with vancomycin. Rev Infect Dis 1981; 3:5273-81.
7. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002; 347:145.
8. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidzaole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2:1043-6.
9. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison vancomycin, teicoplanin, metronidazole, an fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
10. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25(Suppl 2):S206-10.
11. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36:673-9.
12. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
13. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-57.
14. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.
15. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.
16. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis 2005; 40:1598-600.
17. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64.
18. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71-5.
19. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive introcoloic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35:690-6.
20. Fekety R, McFarland LV, surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33.
21. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN, Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159:340-3.
22. Bartlett JG, Chang TW, Onderdonk AB. Comparison of five regimens for t Treatment of experiemental clindamycin-associated colitis. J Infect Dis 1978; 138:81-6.
23. Bartlett JG, Chang TW, Moon N, Onderdonk AB. Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res 1978; 39:1525-30.
24. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54:905-6.
25. Aas J, Gessert CE, Bakken JS. Recurrent Costridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:580-5.
26. Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl 1980; Suppl 22:41-5.
27. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49:640-5.
28. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-7.
29. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
30. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
31. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficle-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005; 173:1037-42.
32. Eggertson L. Quebec strain of C. difficile in 7 provinces. CMAJ 2006; 174:607-8.
33. Pepin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
34. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-8.
35. Musher DM, Logan N, Hamill R et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43:421-7 (in this issue).
36. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:411-20 (in this issue).
37. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001; 45:2340-7.
38. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982; 69:137-9.
39. Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB. Toxin binding of tolevamer, a polyanionic drug that protect against antibiotic- associated diarrhea. Biophys J 2004; 87:534-9.
40. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhea. Br Med J 1978; 2:1667-9.